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New Insights into Nuclear factor erythroid 2-related factors in 1 
Toxicology and Pharmacology 2 
The cap’n’collar-basic region leucine zipper (CNC-bZIP) family of transcription factors 3 
includes the founding member Nuclear factor-erythroid 2 (NF-E2) p45, NF-E2 p45-related factor 4 
1 (Nrf1; also known as NFE2L1, LCRF1, TCF11, HBZ17 or FLJ00380), Nrf2 and Nrf3 (also 5 
abbreviated as NFE2L2 and NFE2L3, respectively), and the more distantly related members BTB 6 
(i.e., Broad complex, Tramtrack, and Bric-à-Brac) domain and CNC homolog 1 (BACH1) and 7 
BACH2 (Tebay et al., 2015; Katsuoka and Yamamoto, 2016; Zhang and Xiang, 2016; Zhu et al., 8 
2016; Yamamoto et al., 2018). In the last two decades, our understanding of CNC-bZIP proteins 9 
has advanced enormously, and our appreciation of their physiological significance has similarly 10 
increased. The primary objective of this special issue (SI) is to stimulate continuing effort to 11 
understand the toxicological and pharmacological roles of CNC-bZIP proteins, and that of Nrf2 12 
and Nrf1 in particular. 13 
Nrf2 is normally found in the cytoplasm of mammalian cells, where it associates with the 14 
redox-sensitive Kelch-like ECH-associated protein 1 (Keap1) E3 ubiquitin ligase substrate 15 
adaptor that polyubiquitinylates Nrf2 and targets it for proteolytic degradation by the 26S 16 
proteasome. This mechanism keeps cellular Nrf2 levels low and prevents Nrf2 accumulation in 17 
the nucleus where it would mediate signaling effects (Suzuki and Yamamoto, 2017; Yamamoto et 18 
al., 2018). In response to a wide variety of oxidative and electrophilic insults, Nrf2 avoids Keap1-19 
mediated proteolytic digestion and accumulates in the nucleus where it heterodimerizes with 20 
small musculoaponeurotic fibrosarcoma (MAF) proteins and binds to antioxidant response 21 
element (ARE; 5′-TGACNNNGC-3′) sequences within target genes, resulting in expression of 22 
that gene for a limited period (Suzuki and Yamamoto, 2017; Yamamoto et al., 2018). The target 23 
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genes of Nrf2 include those that encode a variety of antioxidant and detoxification enzymes. Thus, 24 
the Keap1-Nrf2 system is recognized as a key player in controlling biochemical defense against 25 
exogenous and endogenous electrophilic and oxidative stressors. Importantly, accumulating 26 
evidence indicates that Nrf2 also plays critical roles in regulating expression of numerous genes 27 
involved in cell metabolism, proliferation and differentiation ((Pi et al., 2010; Xue et al., 2013; 28 
Murakami and Motohashi, 2015). 29 
In the Review section of this SI, Ryoo and Kwak revisited recent experimental observations 30 
on the relationship between Nrf2 and mitochondria and discussed mechanisms by which Nrf2 31 
controls mitochondria and metabolism in cancer cells. These authors report that Nrf2 is positively 32 
associated with mitochondrial biogenesis through direct upregulation of mitochondrial 33 
transcription factors and is involved in the mitochondrial quality control system via activation of 34 
mitophagy. Additionally, Nrf2 modulation in cancer cells leads to changes in the mitochondrial 35 
respiratory system and cancer bioenergetics that overall affect cancer metabolism. Ikehata and 36 
Yamamoto reviewed recent progress in the study of contributions by Nrf2 and related factors to 37 
protection against ultraviolet radiation (UVR). The Keap1-Nrf2 system is not always efficient in 38 
responding to UVR, especially to short wavelengths such as UVC and UVB, indicating that UVR 39 
is a poor activator of the Keap1-Nrf2 system. However, sustained activation of Nrf2 appears to 40 
suppress the harmful effects of chronic UVR exposure, such as photoaging and carcinogenesis in 41 
the skin, indicating that Nrf2 activation is beneficial for the protection of the skin from the 42 
harmful effects of UVR. However, sustained activation of Nrf2 may also adversely affect the skin, 43 
especially in the case of UVR-induced carcinogenesis. Sun et al. assessed the roles of Nrf2 in the 44 
development of alcoholic liver disease (ALD) and emphasized that Nrf2 in different cell types in 45 
the liver may play paradoxical roles in the progression of ALD. In the early stages of ALD, Nrf2 46 
in hepatocytes plays a crucial role in regulating redox balance and lipid metabolism. With the 47 
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progression to steatohepatitis, the role of Nrf2 in Kupffer cells become evident, which alleviates 48 
the inflammatory response in the liver. During end-stage ALD, Nrf2 in hepatic stellate cells may 49 
be critical in modulating fibrogenesis. In light of the important protective roles of Nrf2 against 50 
oxidative damage, the study and validation of possible pharmacological targets that would restore 51 
the coordination of the networks in related pathologies has recently received particular attention. 52 
In the review by Yamawaki et al., they summarized the current issues in the treatment of kidney 53 
diseases, Nrf2 activators as treatment options, and perspectives on pharmaceutical applications of 54 
Nrf2 activators. 55 
In the Research Articles section of this SI, Raghunath et al. identified ARE sequences in all 56 
protein-coding genes in the zebrafish genome. They found multiple unique AREs that have not 57 
been reported previously in cytoprotective genes of this organism. In a detailed mechanistic study, 58 
McMahon et al. uncovered that Keap1 directly senses Zn2+ through a cluster of amino-acids that 59 
include His-225, Cys-226 and Cys-613. They presented evidence that binding of Zn2+ triggers a 60 
conformational switch in Keap1, which is envisaged to perturb the architecture of the cullin-3 61 
RING ubiquitin ligase (CRL) complex CRLKeap1, such that bound Nrf2 becomes mis-aligned with 62 
respect to the ubiquitin-charged E2 enzyme. The data are consistent with the notion that Keap1 63 
possesses a Zn2+ sensor whose triggering distorts its structure in a fashion that inhibits 64 
ubiquitylation of Nrf2 upon the CRLKeap1 complex. Chen’s group explored the role of Nrf2 in 65 
mediating aberrant hematopoiesis in response to low-dose benzene exposure in Nrf2-KO mice. 66 
They found that the hematotoxicity of low-dose benzene seems to decrease in Nrf2-KO mice 67 
based on peripheral blood cell counts, despite the fact that oxidative and DNA damage was 68 
significantly enhanced in the mutant mice. In addition, deficiency of Nrf2 triggered proliferation 69 
and differentiation of hematopoietic cells by accelerating cell cycle progression and induced a 70 
morphological abnormality in peripheral erythrocytes and bone marrow cells, implicating 71 
3
compensatory changes that allow induction of dysfunctional defective blood cells. In an in vitro 72 
study, Meng’s group reported that rat primary microglia and astrocytes display different 73 
responses to lead toxicity. In another in vitro study, Zhao’s group examined the role of the Nrf2 74 
signaling pathway in the cytotoxicity induced by the hypoxia mimetic cobalt chloride (CoCl2) in 75 
human keratinocyte HaCaT cells. These workers found that stable knockdown (KD) of Nrf2 76 
dramatically reduced expression of antioxidant enzymes and sensitized the cells to acute CoCl2-77 
induced oxidative stress and cytotoxicity, whereas Keap1-KD cells showed enhanced expression 78 
of ARE-driven genes and resistance to CoCl2-induced cell damage. In addition, pretreatment of 79 
HaCaT cells with tert-butylhydroquinone protected these cells from CoCl2-induced cell injury in 80 
an Nrf2-dependent fashion. In a systematic in vivo study, Cho et al. demonstrated that 81 
sulforaphane (SFN) significantly reduced acute lung injury-like phenotypes caused by subsequent 82 
hyperoxia exposure in an Nrf2-dependent manner. Differential lung transcriptome changes 83 
induced by SFN in wildtype and Nrf2-KO mice suggested that it acts through Nrf2 enhancing 84 
pulmonary mitochondrial dynamics and metabolism to maintain the bioenergetic demands of lung 85 
cells against oxidative stress. As a part of a series of studies on ARE inhibitors from Pi’s 86 
laboratory, Zhu et al. identified a traditional Chinese medicine, triptolide, as an effective and 87 
potent Nrf2-ARE inhibitor. Importantly, triptolide, at non-toxic levels, markedly sensitized non-88 
small-cell lung cancer cells to chemotherapeutic treatments in vitro and in a xenograft mouse 89 
tumor model. 90 
Nrf1 serves as a unique vital player in maintaining cellular homeostasis and organ integrity 91 
during normal development and cell growth throughout life. Global loss of Nrf1 results in severe 92 
oxidative stress, genomic instability, embryonic lethality and developmental disorders. 93 
Conditional knockout of Nrf1 results in adult diseases such as non-alcoholic steatohepatitis, 94 
hepatocellular carcinoma, pancreatic β-cell and adipocyte dysfunction and neurogenerative 95 
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diseases (Pi et al., 2010; Xue et al., 2013; Murakami and Motohashi, 2015; Zheng et al., 2015; 96 
Kim et al., 2016; Fu et al., 2018; Hou et al., 2018; Wang et al., 2018). Thus, Nrf1 is critically 97 
implicated in a variety of important physio-pathological processes by governing expression of 98 
crucial genes in order to reinforce antioxidant, detoxification and cytoprotective responses to 99 
cellular stress. Of clinical interest, Nrf1 mediates the proteasomal ‘bounce-back’ response, 100 
leading to drug resistance to proteasomal inhibitors for clinical treatment of neuroblastoma, 101 
multiple myeloma and triple-negative breast cancers (Steffen et al., 2010; Bugno et al., 2015; 102 
Sekine et al., 2018). During its translation, Nrf1 is targeted to the endoplasmic reticulum (ER) 103 
and subject to extensive post-translational modification before it regulates its target genes. 104 
However, the mechanisms whereby Nrf1 is processed and topologically released from the ER 105 
before entering the nucleus is hotly debated. In this SI, a series of experiments from Zhang's 106 
laboratory demonstrate the maturation processing of Nrf1 to remove its N-terminal ~12.5-kDa 107 
and longer polypeptides. The authors have further elucidated topo-vectorial mechanisms that 108 
monitor dynamic movement of Nrf1 in and out of the ER lumen, as well as the selective 109 
proteolytic processing of the CNC-bZIP protein to remove distinct lengths of its NTD (most of 110 
which was refolded as a UBL module) and PEST-adjoining AD1 domains. More importantly, 111 
they have also established a general criterion acceptable for identification of the endogenous 112 
Nrf1α/TCF11 and derivative isoforms, with distinct molecular weights and half-lives determined 113 
in various experimental cellular settings. Furthermore, they propose that coupled positive and 114 
negative feedback circuits exist between Nrf1 and its target genes. These results suggest Nrf1 is 115 
subject to dual opposing control in which low doses of proteasomal inhibitors elicit a 'bounce-116 
back' response but higher doses inhibit the transcription factor. Collectively, the findings from 117 
Zhang’s group suggest the potential of Nrf1 to be developed as a new target for chemoprevention 118 
and therapy of cancers and other diseases. 119 
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Coordinately dealing with fluctuating levels of numerous metabolic and environmental 120 
stresses is critical for the survival of cells and whole organisms. Perturbations in redox balance 121 
may impair cellular homeostasis and trigger the onset of disease. Accordingly, cells have 122 
developed multiple and well-conserved mechanisms that regulate adaptive antioxidant responses. 123 
Oxidative stress, which is defined as a general response to internal and environmental oxidative 124 
challenges, is involved in triggering adaptation to oxidative damage. On the other hand, persistent 125 
oxidative stress may lead to disruption of redox signaling and loss of homeostatic mechanisms 126 
(Zhang et al., 2010; Fu et al., 2016). Thus, precise coordination of cellular adaptive responses to 127 
oxidative insults promotes stress resistance and recovery of homeostasis, whereas persistent 128 
adaptation would have a cost that may be involved in the pathogenesis of many chronic disorders 129 
(see Figure 1). 130 
For many decades, ROS were considered cytotoxic waste products arising from cellular 131 
processes. Thus, antioxidant interventions were established in the settings of aging and chronic 132 
diseases. However, animal studies and epidemiological investigations on the therapeutic 133 
outcomes of antioxidant interventions have provided data that contradict the view that ROS are 134 
merely of toxicological significance, questioning long-standing beliefs of an ultimate beneficial 135 
role for antioxidant therapies in health and disease (Zhang et al., 2010; Fu et al., 2016). In 136 
agreement with the aforementioned accumulating evidence and in the context of major chronic 137 
diseases, we reasonably hypothesized that persistent activation of Nrfs-ARE caused by 138 
environmental stressors may be involved in the pathogenesis of various chronic diseases, such as 139 
Type 2 diabetes and malignant tumors (see Figure 1). Of course, coordinated efforts are needed to 140 
clarify the exact roles of various isoforms of Nrfs in the development and intervention of various 141 
chronic diseases. 142 
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In summary, while significant progress has been made in terms of elucidating how the 143 
different Nrf transcription factors (in particular Nrf2, and to a much lesser extent Nrf1) regulate 144 
the antioxidant response, critical questions still remain. Most obviously, we know relatively little 145 
about NF-E2 p45, Nrf3, BACH1 and BACH2. Other important open issues relating to Nrfs in 146 
toxicology and pharmacology may include, but are not limited to: (1) determining the spectrum of 147 
target genes of Nrfs in different cells under diverse stress challenges, and the potential 148 
involvement of Nrfs in regulating genes independently of ARE sequences; (2) the mechanistic 149 
aspects of the complex regulatory network of Nrfs-mediated transcription under basal 150 
physiological conditions and under adaptive response conditions; (3) the transcriptional 151 
regulation of Nrfs under a sustained stress challenge, in particular the involvement of non-coding 152 
RNAs, such as miRNAs; (4) the crosstalk between Nrfs and other stress response machinery in 153 
response to various internal and environmental challenges; (5) the toxicological significance and 154 
application of Nrfs network perturbation in toxicity testing; (6) the characterization of the cell-155 
specific physiological functions of different isoforms of Nrf1; (7) identification and application 156 
of novel modulators targeting specifically the transcriptional activity of various isoforms of 157 
Nrfs; (8) precise phenotyping of cell-specific knockout or overexpression of Nrfs in a variety of 158 
disease models; and (9) identification and characterization of functional SNPs and epigenetic 159 
sites in the human genes of Nrfs.  160 
  161 
Guest-Editors:  162 
Jingbo Pi, M.D., Ph.D. 163 
School of Public Health, 164 
China Medical University 165 
7
P.R. China 166 
Phone: 0086-18900910300 167 
Email: jbpi@cmu.edu.cn; jingbopi@163.com 168 
 169 
John D Hayes, Ph.D 170 
Jacqui Wood Cancer Centre,  171 
Division of Cellular Medicine,  172 
Ninewells Hospital and Medical School, 173 
University of Dundee, Dundee DD1 9SY,  174 
Scotland,  175 
U.K. 176 
Email: j.d.hayes@dundee.ac.uk 177 
 178 
Masayuki Yamamoto, Ph.D 179 
Department of Medical Biochemistry,  180 
Tohoku University Graduate School of Medicine,  181 
Sendai 980-8575,  182 
Japan 183 
Email: masiyamamoto@med.tohoku.ac.jp 184 
 185 
8
 186 
References : 187 
Bugno, M., Daniel, M., Chepelev, N. L., and Willmore, W. G. (2015). Changing gears in 188 
Nrf1 research, from mechanisms of regulation to its role in disease and 189 
prevention. Biochimica et biophysica acta 1849, 1260-1276. 190 
Fu, J., Hou, Y., Xue, P., Wang, H., Xu, Y., Qu, W., Zhang, Q., and Pi, J. (2016). Nrf2 in 191 
Type 2 diabetes and diabetic complications: Yin and Yang Current Opinion in 192 
Toxicology 1, 9-19. 193 
Fu, J., Zheng, H., Cui, Q., Chen, C., Bao, S., Sun, J., Li, L., Yang, B., Wang, H., Hou, Y., 194 
Xu, Y., Xu, Y., Zhang, Q., and Pi, J. (2018). Nfe2l1-silenced insulinoma cells 195 
acquire aggressiveness and chemoresistance. Endocrine-related cancer 25, 185-196 
200. 197 
Hou, Y., Liu, Z., Zuo, Z., Gao, T., Fu, J., Wang, H., Xu, Y., Liu, D., Yamamoto, M., Zhu, 198 
B., Zhang, Y., Andersen, M. E., Zhang, Q., and Pi, J. (2018). Adipocyte-specific 199 
deficiency of Nfe2l1 disrupts plasticity of white adipose tissues and metabolic 200 
homeostasis in mice. Biochemical and biophysical research communications 503, 201 
264-270. 202 
Katsuoka, F., and Yamamoto, M. (2016). Small Maf proteins (MafF, MafG, MafK): 203 
History, structure and function. Gene 586, 197-205. 204 
Kim, H. M., Han, J. W., and Chan, J. Y. (2016). Nuclear Factor Erythroid-2 Like 1 205 
(NFE2L1): Structure, function and regulation. Gene 584, 17-25. 206 
Murakami, S., and Motohashi, H. (2015). Roles of Nrf2 in cell proliferation and 207 
differentiation. Free radical biology & medicine 88, 168-178. 208 
Pi, J., Leung, L., Xue, P., Wang, W., Hou, Y., Liu, D., Yehuda-Shnaidman, E., Lee, C., 209 
Lau, J., Kurtz, T. W., and Chan, J. Y. (2010). Deficiency in the nuclear factor E2-210 
related factor-2 transcription factor results in impaired adipogenesis and protects 211 
against diet-induced obesity. The Journal of biological chemistry 285, 9292-9300. 212 
Sekine, H., Okazaki, K., Kato, K., Alam, M. M., Shima, H., Katsuoka, F., Tsujita, T., 213 
Suzuki, N., Kobayashi, A., Igarashi, K., Yamamoto, M., and Motohashi, H. 214 
(2018). O-GlcNAcylation Signal Mediates Proteasome Inhibitor Resistance in 215 
Cancer Cells by Stabilizing NRF1. Molecular and cellular biology. 216 
Steffen, J., Seeger, M., Koch, A., and Kruger, E. (2010). Proteasomal degradation is 217 
transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. 218 
Molecular cell 40, 147-158. 219 
Suzuki, T., and Yamamoto, M. (2017). Stress-sensing mechanisms and the physiological 220 
roles of the Keap1-Nrf2 system during cellular stress. The Journal of biological 221 
chemistry 292, 16817-16824. 222 
Tebay, L. E., Robertson, H., Durant, S. T., Vitale, S. R., Penning, T. M., Dinkova-223 
Kostova, A. T., and Hayes, J. D. (2015). Mechanisms of activation of the 224 
transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and 225 
the pathways through which it attenuates degenerative disease. Free radical 226 
biology & medicine 88, 108-146. 227 
9
Wang, H., Zhu, J., Liu, Z., Lv, H., Lv, P., Chen, F., Fu, J., Hou, Y., Zhao, R., Xu, Y., 228 
Zhang, Q., and Pi, J. (2018). Silencing of long isoforms of nuclear factor 229 
erythroid 2 like 1 primes macrophages towards M1 polarization. Free radical 230 
biology & medicine 117, 37-44. 231 
Xue, P., Hou, Y., Chen, Y., Yang, B., Fu, J., Zheng, H., Yarborough, K., Woods, C. G., 232 
Liu, D., Yamamoto, M., Zhang, Q., Andersen, M. E., and Pi, J. (2013). Adipose 233 
deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. Diabetes 234 
62, 845-854. 235 
Yamamoto, M., Kensler, T. W., and Motohashi, H. (2018). The KEAP1-NRF2 System: a 236 
Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. 237 
Physiological reviews 98, 1169-1203. 238 
Zhang, Q., Pi, J., Woods, C. G., and Andersen, M. E. (2010). A systems biology 239 
perspective on Nrf2-mediated antioxidant response. Toxicol Appl Pharmacol 244, 240 
84-97. 241 
Zhang, Y., and Xiang, Y. (2016). Molecular and cellular basis for the unique functioning 242 
of Nrf1, an indispensable transcription factor for maintaining cell homoeostasis 243 
and organ integrity. The Biochemical journal 473, 961-1000. 244 
Zheng, H., Fu, J., Xue, P., Zhao, R., Dong, J., Liu, D., Yamamoto, M., Tong, Q., Teng, 245 
W., Qu, W., Zhang, Q., Andersen, M. E., and Pi, J. (2015). CNC-bZIP protein 246 
Nrf1-dependent regulation of glucose-stimulated insulin secretion. Antioxid Redox 247 
Signal 22, 819-831. 248 
Zhu, J., Wang, H., Chen, F., Fu, J., Xu, Y., Hou, Y., Kou, H. H., Zhai, C., Nelson, M. B., 249 
Zhang, Q., Andersen, M. E., and Pi, J. (2016). An overview of chemical inhibitors 250 
of the Nrf2-ARE signaling pathway and their potential applications in cancer 251 
therapy. Free radical biology & medicine 99, 544-556. 252 
253 
10
Figure legends : 254 
Figure 1. Nrfs may play paradoxical Yin-and-Yang roles in the development of oxidative 255 
stress-related disorders. Yin-side of ROS: Prolonged overproduction of ROS may result in 256 
oxidative damage and even cell death, leading to impaired cell function; Yang-side of ROS: 257 
Transient ROS production in response to various stimuli may function as signals mediating 258 
cellular responses. Yin-side of antioxidants: Antioxidants may blunt ROS signaling in the cell; 259 
Yang-side of antioxidants: Antioxidants may generally protect cells against oxidative damage. 260 
Yin-side of Nrfs: Chronic activation of Nrfs-mediated antioxidant response under persistent 261 
oxidative stress may blunt normal ROS signaling in the cell; Yang-side of Nrfs: Nrfs activation 262 
and subsequent induction of antioxidants may protect cells from oxidative damage.  263 
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